Drug Type Monoclonal antibody |
Synonyms |
Target |
Action antagonists |
Mechanism α4β1 antagonists(Integrin alpha-4/beta-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 1 | United States | 30 Oct 2020 |